The Centers for Medicare & Medicaid Services Friday released guidance clarifying federal requirements for health plans to cover certain items and services related to diagnostic testing for COVID-19 without cost-sharing, prior authorization or other medical management requirements.

The guidance also includes information on federal reimbursement for COVID-19-related services provided to the uninsured.

In other news, the Food and Drug Administration today issued an emergency use authorization for the Quidel QuickVue At-Home COVID-19 Test, a prescription antigen test that allows individuals to collect and test a sample at home when their health care provider suspects they have COVID-19 within six days of symptom onset.

The EUA requires Quidel to develop a mobile phone application or website to facilitate results reporting by the user and health care provider. A research team funded by the National Institutes of Health has launched a study to assess the app’s performance and usability.

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…